Treatment of Tourette syndrome with neuroleptic drugs
Erenberg, G.
Advances in Neurology 58: 241-243
1992
ISSN/ISBN: 0091-3952 PMID: 1357939 Document Number: 401298
Document emailed within 1 workday
Related Documents
Lavie, C.J.; Ventura, H.O.; Walker, G. 1986: Neuroleptic malignant syndrome: three episodes with different drugs Southern Medical Journal 79(12): 1571-1573Janssen, P.A.; Niemegeers, C.J.; Schellekens, K.H. 1965: Is it Possible to Predict the Clinical Effects of Neuroleptic Drugs (Major Tranquillizers) from Animal Data?i. "neuroleptic Activity Spectra" for Rats Arzneimittel-Forschung 15: 104-117
Bruun, R.D.; Budman, C.L. 1996: Risperidone as a treatment for Tourette's syndrome Journal of Clinical Psychiatry 57(1): 29-31
Barbeau, A. 1980: Cholinergic treatment in the Tourette syndrome New England Journal of Medicine 302(23): 1310-1311
Bhidayasiri, R.; Locharernkul, C.; Phanthumchinda, K. 2005: Tourette's syndrome: old syndrome, new insights and new treatment Journal of the Medical Association of Thailand 88(10): 1462-1470
Borison, R.L.; Ang, L.; Chang, S.; Dysken, M.; Comaty, J.E.; Davis, J.M. 1982: New pharmacological approaches in the treatment of Tourette syndrome Advances in Neurology 35: 377-382
Sverd, J. 1988: Imipramine treatment of panic disorder in a boy with Tourette's syndrome Journal of Clinical Psychiatry 49(1): 31-32
Paolucci, S.; Buttinelli, C.; Fiume, S.; Ciani, S.; Lenzi, G.L. 1984: Treatment of Gilles de la Tourette syndrome with depot neuroleptics Acta Neurologica 6(3): 222-224
Cappabianca, P.; Spaziante, R.; Carrabs, G.; de Divitiis, E. 1987: Surgical stereotactic treatment for Gilles de la Tourette's syndrome Acta Neurologica 9(4): 273-280
Lavie, C.J.; Olmsted, T.R.; Ventura, H.O.; Lepler, B.J. 1986: Neuroleptic malignant syndrome. An underdiagnosed reaction to neuroleptic agents? Postgraduate Medicine 80(3): 171-178
Bukowczyk, A.; Wasik, A.; Horodnicki, J. 1974: Clinical evaluation of amantadine in the treatment of extrapyramidal syndromes caused by neuroleptic drugs Psychiatria Polska 8(2): 143-148
Ben Hadj Ali, B.; Dogui, M.; Ben Ammou, S.; Lôo, H. 1995: Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal L'Encephale 21(3): 209-215
Drtil, M.; Vinar, O.; Taussigová, D. 1973: Maintenance treatment with long-acting neuroleptic drugs in persons with disturbances of social behavior and drug dependence Activitas Nervosa Superior 15(2): 87
Emborg, C. 1999: Neuroleptic malignant syndrome after treatment with olanzapine Ugeskrift for Laeger 161(10): 1424-1425
Leikin, J.B.; Baron, S.; Engle, J.; Zell, M.; Hryhorczuk, D.O. 1988: Treatment of neuroleptic malignant syndrome with diphenhydramine Veterinary and Human Toxicology 30(1): 58-59
Guerrero, R.M.; Shifrar, K.A. 1988: Diagnosis and treatment of neuroleptic malignant syndrome Clinical Pharmacy 7(9): 697-701
Sakkas, P.; Davis, J.M.; Janicak, P.G.; Wang, Z.Y. 1991: Drug treatment of the neuroleptic malignant syndrome Psychopharmacology Bulletin 27(3): 381-384
Blümlein, G. 1997: Successful use of amantadine in treatment of malignant neuroleptic syndrome Psychiatrische Praxis 24(5): 257-258
Mueller, P.S.; Vester, J.W.; Fermaglich, J. 1983: Neuroleptic malignant syndrome. Successful treatment with bromocriptine JAMA 249(3): 386-388
Gram, L.F. 2000: Malignant neuroleptic syndrome in treatment with the new, atypical antipsychotic agents, risperidone and olanzapine Ugeskrift for Laeger 162(13): 1914-1915